share_log

Grail | 10-Q: Quarterly report

Grail | 10-Q: Quarterly report

Grail | 10-Q：季度报表
美股SEC公告 ·  2024/08/13 17:03

Moomoo AI 已提取核心信息

GRAIL reported Q2 2024 revenue of $32.0 million, up 43% year-over-year, driven by increased Galleri test volume. Screening revenue grew 41% to $28.2 million while development services revenue increased 59% to $3.8 million. The company recorded a net loss of $1.6 billion, primarily due to a $1.4 billion goodwill and intangible asset impairment charge.Following a portfolio review, GRAIL announced a restructuring plan to focus on its core multi-cancer early detection business and reduce costs. The plan includes a 30% reduction in workforce and planned hires, affecting approximately 350 current employees. The company expects annual cost savings of $120 million and projects the restructuring will extend its cash runway from 2026 into 2028.As of June 30, 2024, GRAIL had $958.8 million in cash and cash equivalents, bolstered by $932.3 million in disposal funding received from Illumina in connection with the spin-off completed on June 24, 2024. The company has sold over 215,000 commercial Galleri tests to date and established more than 140 commercial partnerships with healthcare systems, employers, payors and life insurance providers.
GRAIL reported Q2 2024 revenue of $32.0 million, up 43% year-over-year, driven by increased Galleri test volume. Screening revenue grew 41% to $28.2 million while development services revenue increased 59% to $3.8 million. The company recorded a net loss of $1.6 billion, primarily due to a $1.4 billion goodwill and intangible asset impairment charge.Following a portfolio review, GRAIL announced a restructuring plan to focus on its core multi-cancer early detection business and reduce costs. The plan includes a 30% reduction in workforce and planned hires, affecting approximately 350 current employees. The company expects annual cost savings of $120 million and projects the restructuring will extend its cash runway from 2026 into 2028.As of June 30, 2024, GRAIL had $958.8 million in cash and cash equivalents, bolstered by $932.3 million in disposal funding received from Illumina in connection with the spin-off completed on June 24, 2024. The company has sold over 215,000 commercial Galleri tests to date and established more than 140 commercial partnerships with healthcare systems, employers, payors and life insurance providers.
GRAIL报告2024年第二季度营业收入为3200万美元，同比增长43%，这得益于Galleri测试成交量的增加。筛查营业收入增长了41%，达到2820万美元，而开发服务营业收入增加了59%，达到380万美元。公司记录的净亏损为16亿，主要由于14亿美元的商誉和无形资产减值费用。经过投资组合审查，GRAIL宣布了一项重组计划，以专注于其核心的多癌种早期检测业务并降低成本。该计划包括将劳动力和计划招聘减少30%，影响约350名现有员工。公司预计每年可节省12000万美元的成本，并预计重组将把其现金储备从2026年延长到2028年。截至2024年6月30日，GRAIL的现金及现金等价物为95880万美元，因收到来自Illumina的93230万美元处置资金而加强，这与2024年6月24日完成的分拆相关。公司迄今已售出超过215,000个商业Galleri测试，并与医疗系统、雇主、支付方和人寿保险提供者建立了140多个商业合作伙伴关系。
GRAIL报告2024年第二季度营业收入为3200万美元，同比增长43%，这得益于Galleri测试成交量的增加。筛查营业收入增长了41%，达到2820万美元，而开发服务营业收入增加了59%，达到380万美元。公司记录的净亏损为16亿，主要由于14亿美元的商誉和无形资产减值费用。经过投资组合审查，GRAIL宣布了一项重组计划，以专注于其核心的多癌种早期检测业务并降低成本。该计划包括将劳动力和计划招聘减少30%，影响约350名现有员工。公司预计每年可节省12000万美元的成本，并预计重组将把其现金储备从2026年延长到2028年。截至2024年6月30日，GRAIL的现金及现金等价物为95880万美元，因收到来自Illumina的93230万美元处置资金而加强，这与2024年6月24日完成的分拆相关。公司迄今已售出超过215,000个商业Galleri测试，并与医疗系统、雇主、支付方和人寿保险提供者建立了140多个商业合作伙伴关系。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    ProPhase Labs
    PRPH
    -- 0.360
    Applied DNA Sciences
    APDN
    -- 2.042
    Star Equity
    STRR
    -- 2.6400
    Personalis
    PSNL
    -- 3.860
    Aclaris Therapeutics
    ACRS
    -- 1.730
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日